A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

Depression and Anxiety

Volumn 24, Issue 1, 2007, Pages 1-14

  Pollack, Mark H ^a   Lepola, Ulla ^b   Koponen, Hannu ^c   Simon, Naomi M ^a   Worthington, John J ^a   Emilien, Gerard ^d   Tzanis, Evan ^e   Salinas, Eliseo ^e   Whitaker, Timothy ^e   Gao, Bo ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d Clinical Research and Development   (France)

^e PFIZER INC   (United States)

Author keywords

Anxiety; Panic disorder; Paroxetine; Venlafaxine ER

Indexed keywords

PAROXETINE; PLACEBO; VENLAFAXINE;

ADULT; AGORAPHOBIA; ANOREXIA; ANORGASMIA; ANTICIPATORY ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BACKACHE; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION DISORDER; FEMALE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORGASM DISORDER; PANIC; PANIC AND ANTICIPATORY ANXIETY SCALE; PANIC DISORDER SEVERITY SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGORAPHOBIA; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PERSONALITY INVENTORY; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33847108539     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20218     Document Type: Article

References (66)

1. American Psychiatric Association. 1998. Practice guideline for the treatment of patients with panic disorder [Work Group on Panic Disorder]. Am J Psychiatry 155:1-34.
2. Allgulander C, Hackett D, Salinas E. 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15-22.
3. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G. 2004. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387-396.
4. Ball SG, Otto MW, Pollack MH, Rosenbaum JF. 1994. Predicting prospective episodes of depression in patients with panic disorder: A longitudinal study. J Consult Clin Psychol 62:359-365.
5. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK. 1998a. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59:47-54.
6. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU. 2001. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 62(Suppl 11):53-58.
7. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. 1998b. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42.
8. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171-199.
9. Barlow DH, Gorman JM, Shear MK, Woods SW 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283:2529-2536.
10. Black DW, Wesner R, Bowers W, Gabel J. 1993. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50.
11. Boyer P, Mahe V, Hackett D. 2004. Social adjustment in generalised anxiety disorder: A long-term placebo-controlled study of venlafaxine extended release. Eur Psychiatry 19:272-279.
12. Breier A, Charney DS, Heninger GR. 1984. Major depression in patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:1129-1135.
13. Breier A, Charney DS, Heninger GR. 1986. Agoraphobia with panic attacks: Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 43:1029-1036.
14. Candilis PJ, McLean RY, Otto MW, Manfro GG, Worthington JJ 3, Penava SJ, Marzol PC, Pollack MH. 1999. Quality of life in patients with panic disorder. J Nerv Ment Dis 187:429-434.
15. den Boer JA. 1998. Pharmacotherapy of panic disorder: Differential efficacy from a clinical viewpoint. J Clin Psychiatry 59(Suppl 8):30-36.
16. Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 29:321-326.
17. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283:3082-3088.
18. Geracioti TD Jr. 1995. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 56:408-410.
19. Guy W, editor. 1976. Clinical Global Impressions (CGI): ECDEU Assessment manual for psychopharmacology. Rev. ed. Washington, DC: U.S. Department of Health, Education and Welfare, National Institute of Mental Health, p 217-222.
20. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
21. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
22. Jobson KO, Davidson JR, Lydiard RB, McCann UD, Pollack MH, Rosenbaum JF. 1995. Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 31:483-485.
23. Katon W, Vitaliano PP, Russo J, Cormier L, Anderson K, Jones M. 1986. Panic disorder: Epidemiology in primary care. J Fam Pract 23:233-239.
24. Kelsey JE. 1996. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 16:21S-26S.
25. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
26. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM. 1998. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study [Venlafaxine Investigator Study Group]. J Clin Psychopharmacol 18:19-25.
27. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. 1991. Panic attacks in the community: Social morbidity and health care utilization. JAMA 265:742-746.
28. Lecrubier Y, Bakker A, Dunbar G, Judge R. 1997. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder [Collaborative Paroxetine Panic Study Investigators]. Acta Psychiatr Scand 95:145-152.
29. Lecrubier Y, Judge R. 1997. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder [Collaborative Paroxetine Panic Study Investigators]. Acta Psychiatr Scand 95:153-160.
30. Liebowitz MR, Gelenberg AJ, Munjack D. 2005a. Venlafaxine vs paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190-198.
31. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. 2005b. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238-247.
32. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C. 1998. Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54-60.
33. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. 1989. Quality of life in panic disorder. Arch Gen Psychiatry 46:984-992.
34. Marks IM, Mathews AM. 1979. Brief standard self-rating for phobic patients. Behav Res Ther 17:263-267.
35. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic VR, Timotijevic I, Sarkar N, Skoglund L, Pemberton SC. 2001. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial. Br J Psychiatry 179:514-518.
36. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD. 1998. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo [Fluoxetine Panic Disorder Study Group]. Am J Psychiatry 155:1570-1577.
37. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G. 1999. Continuing treatment of panic disorder after acute response: Randomised, placebo-controlled trial with fluoxetine [Fluoxetine Panic Disorder Study Group]. Br J Psychiatry 174:213-218.
38. Montgomery SA, Mahe V, Haudiquet V, Hackett D. 2002a. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: Results of a survival analysis. J Clin Psychopharmacol 22:561-567.
39. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. 2002b. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 36:209-217.
40. Oehrberg S, Chrisnansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM. 1995. Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374-379.
41. Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM. 1998. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34:207-209.
42. Pohl RB, Wolkow RM, Clary CM. 1998. Sertraline in the treatment of panic disorder: A double-blind multicenter trial. Am J Psychiatry 155:1189-1195.
43. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP. 2003. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8:17-30.
44. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. 1998. Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial. Arch Gen Psychiatry 55:1010-1016.
45. Pollack MH, Worthington JJ 3, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF. 1996. Venlafaxine for panic disorder: Results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667-670.
46. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. 2001. Sertraline treatment of panic disorder: Results of a long-term study. Acta Psychiatr Scand 104:289-298.
47. Rickels K, Mangano R, Khan A. 2004. Double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488-496.
48. Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974.
49. Roy-Byrne PP, Wagner AW, Schraufhagel TJ. 2005. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 66(Suppl 4):16-22.
50. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. 1998. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122.
51. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. 1997. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 47:150-155.
52. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA. 1997. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571-1575.
53. Sheehan DV 1983. The anxiety disease. New York: Scribners Sons.
54. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33.
55. Sheikh JI, Londborg P, Clary CM, Fayyad R. 2000. The efficacy of sertraline in panic disorder: Combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335-342.
56. Simon NM, Pollack MH. 1999. Treatment-refractory panic disorder. Psychiatr Clin North Am 6:115-139.
57. Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD, Pollack MH. 2002. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 69:201-208.
58. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. 2002. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry 180:396-404.
59. Stahl SM, Gergel I, Li D. 2003. Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327.
60. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. 2005. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280-288.
61. Stein MB, Tancer ME, Uhde TW. 1990. Major depression in patients with panic disorder: Factors associated with course and recurrence. J Affect Disord 19:287-296.
62. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK. 2003. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258.
63. Thase ME, Entsuah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
64. Tiller JW, Bouwer C, Behnke K. 1999. Moclobemide and flouxetine for panic disorder [International Panic Disorder Study Group]. Eur Arch Psychiatry Clin Neurosci 249(Suppl 1):7-10.
65. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. 1997. The effect of citalopram in panic disorder. Br J Psychiatry 170:549-553.
66. Weissman MM. 1991. Panic disorder: Impact on quality of life. J Clin Psychiatry 52:6-8.